Research Analysts Set Expectations for Immunocore Holdings plc’s FY2028 Earnings (NASDAQ:IMCR)

Immunocore Holdings plc (NASDAQ:IMCR) – Capital One Financial upped their FY2028 earnings per share (EPS) estimates for shares of Immunocore in a report issued on Thursday, May 2nd. Capital One Financial analyst N. Quibria now forecasts that the company will post earnings of $1.85 per share for the year, up from their prior estimate of $1.66. The consensus estimate for Immunocore’s current full-year earnings is ($1.55) per share.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. upped their target price on Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. SVB Leerink assumed coverage on Immunocore in a research note on Monday, April 29th. They issued an “outperform” rating and a $74.00 price objective on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunocore in a report on Monday, April 29th. Mizuho boosted their price objective on shares of Immunocore from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $81.00 target price on shares of Immunocore in a research note on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $80.92.

Immunocore Stock Performance

NASDAQ:IMCR opened at $60.23 on Monday. Immunocore has a twelve month low of $42.21 and a twelve month high of $76.98. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $3.00 billion, a P/E ratio of -51.92 and a beta of 0.92. The company has a fifty day moving average of $61.28 and a 200-day moving average of $61.14.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The firm had revenue of $70.16 million for the quarter, compared to analyst estimates of $53.25 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The company’s quarterly revenue was up 22.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.63) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IMCR. FORA Capital LLC purchased a new stake in Immunocore in the 1st quarter worth approximately $777,000. Capstone Investment Advisors LLC purchased a new stake in Immunocore in the first quarter worth $1,227,000. Principal Financial Group Inc. boosted its holdings in Immunocore by 7.0% in the first quarter. Principal Financial Group Inc. now owns 517,204 shares of the company’s stock valued at $33,618,000 after acquiring an additional 33,868 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Immunocore by 69.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after purchasing an additional 2,721 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Immunocore by 2.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 87,614 shares of the company’s stock worth $5,695,000 after purchasing an additional 1,830 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.